Core Viewpoint - Huahai Pharmaceutical experienced a 5.01% decline in stock price, closing at 19.73 CNY per share, with a trading volume of 487 million CNY and a turnover rate of 1.62%, resulting in a total market capitalization of 29.541 billion CNY [1] Group 1: Company Overview - Zhejiang Huahai Pharmaceutical Co., Ltd. was established on February 28, 2001, and went public on March 4, 2003 [1] - The company specializes in the research, production, and sales of various dosage forms of generic drugs, biological drugs, innovative drugs, and specialty raw materials [1] - The revenue composition of the company includes finished drug sales at 61.86%, raw materials and intermediates sales at 36.75%, other revenues at 0.78%, and technical services at 0.62% [1] Group 2: Fund Holdings - Anxin Fund has one fund heavily invested in Huahai Pharmaceutical, specifically Anxin Medical Health Stock A (010709), which reduced its holdings by 250,200 shares in the second quarter, now holding 172,820 shares, representing 3.4% of the fund's net value, ranking as the ninth largest holding [2] - The estimated floating loss for the fund today is approximately 1.7973 million CNY [2] - Anxin Medical Health Stock A was established on January 12, 2021, with a current size of 444 million CNY, achieving a year-to-date return of 64.37%, ranking 201 out of 4220 in its category [2] Group 3: Fund Manager Information - The fund manager of Anxin Medical Health Stock A is Chi Chenshen, who has been in the position for 4 years and 276 days [3] - The total asset size of the fund is 946 million CNY, with the best fund return during the tenure being 56.95% and the worst being 53.28% [3]

Core Insights - The aging population in China is leading to an increase in the prevalence of neurodegenerative diseases, significantly driving the demand for related medications. The market size for neurodegenerative disease drugs in China is projected to reach approximately 10.55 billion yuan in 2024, reflecting a year-on-year growth of 24.12% [1][5]. Industry Overview - Neurodegenerative disease drugs are designed to treat chronic progressive neurological disorders characterized by the degeneration of neurons, including Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis [2][3]. Industry Development History - The neurodegenerative disease drug industry in China has evolved through several phases: - From the 1990s to 2010, the industry began with the introduction of generic drugs to meet clinical needs, supported by regulatory improvements [3]. - From 2010 to 2020, the industry saw advancements in drug approval processes and clinical trial networks, leading to increased research quality and the emergence of innovative therapies [3]. - Since 2020, the focus has shifted towards innovation, with AI-driven drug development and the inclusion of Alzheimer's disease in special medical insurance categories enhancing drug accessibility [3]. Market Size - The market for neurodegenerative disease drugs in China is expected to grow to about 10.55 billion yuan in 2024, with a year-on-year increase of 24.12%. The government's efforts to improve medical insurance policies are expected to further boost market growth by increasing drug accessibility for patients [5][6]. Key Companies and Performance - The competitive landscape of the neurodegenerative disease drug industry is characterized by the rise of domestic innovation and the presence of multinational pharmaceutical companies. Notable domestic companies include: - **Xiansheng Pharmaceutical**: Focuses on early intervention strategies and has a diverse pipeline in the central nervous system area [7]. - **Hengrui Medicine**: Engages in extensive R&D across neurology and pain management, with significant revenue growth and R&D investment [9][10]. - The industry is witnessing a shift towards innovative therapies, with companies like Ruijian Pharmaceutical and Shenji Changhua making breakthroughs in cell therapy for Parkinson's disease [6]. Industry Development Trends 1. **Accelerated Innovation**: The development of neurodegenerative disease drugs is expected to accelerate, with a focus on innovative therapies driven by advancements in biotechnology and artificial intelligence [11]. 2. **Diverse Competitive Landscape**: The market will see increased competition, with domestic companies enhancing their capabilities to compete with international firms [12]. 3. **Policy Support and Regulation**: The government is likely to continue supporting the industry through policies that encourage R&D investment and improve drug accessibility for patients [13].

Group 1 - Jinli Permanent Magnet expects a net profit of 505 million to 550 million yuan for the first three quarters of 2025, representing a year-on-year increase of 157% to 179% [1] - Guangdong Mingzhu anticipates a net profit of 215 million to 263 million yuan for the first three quarters of 2025, with a year-on-year growth of 858.45% to 1,071.44% [1] - Guangda Special Materials forecasts a net profit of approximately 248 million yuan for the first three quarters of 2025, reflecting a year-on-year increase of about 213.92% [2] Group 2 - Taotao Vehicle expects a net profit of 580 million to 620 million yuan for the first three quarters of 2025, indicating a year-on-year growth of 92.46% to 105.73% [2] - Dongfang Wealth has set the initial transfer price at 24.40 yuan per share, which is an 8.9% discount from the closing price [3] - Ganfeng Lithium has established a complete integrated layout for solid-state batteries and possesses commercialization capabilities [3] Group 3 - Huahai Pharmaceutical's subsidiary has received acceptance for the marketing authorization application of a targeted IL-36R antibody, which is the first of its kind developed in China [4][5] - Xingqi Eye Medicine has obtained clinical trial approval for SQ-129, a sustained-release injection for treating diabetic macular edema [6] - Muyuan Foods has raised its forecast for piglet output in 2025 to a range of 12 million to 14.5 million heads [6] Group 4 - Tianhe Magnetic Materials plans to invest 900 million yuan in high-performance rare earth permanent magnet projects [6] - Qianli Technology reported a significant increase in new energy vehicle production, with 4,282 units produced in September 2025, a year-on-year increase of 975.88% [6] - Yongzhen Co. has signed a strategic cooperation agreement with BYD to provide aluminum alloy components for energy storage [6] Group 5 - Xingye Silver Tin's controlling shareholder has completed its restructuring plan without changing the control of the listed company [7] - Jiangxi Copper has experienced significant price increases in its main products, copper cathodes and gold [7] - Saisir has signed a framework agreement with ByteDance's Volcano Engine for collaboration in embodied intelligence [8] Group 6 - Luoyang Molybdenum's production and operational activities remain normal, with no significant fluctuations in production costs or sales [8] - Tongling Nonferrous Metals has reported significant price increases in its main products, copper cathodes and gold, with low processing fees for copper concentrate [8] - New Yisheng has set the initial transfer price at 328 yuan per share, reflecting a 6.6% discount from the closing price [9] Group 7 - Lichong Group has signed a strategic cooperation agreement with Weijing Intelligent to extend its business into humanoid robotics [10] - Poly Development plans to transfer 4.512 billion shares to Poly Group, making it the controlling shareholder [10] - Huajian Group's executives plan to collectively reduce their holdings by 1.05 million shares [10][11]

目前全球范围内，尚未有国内企业自研的靶向IL-36R抗体获批上市。HB0034作为国内首个自研创新抗 IL-36R抗体，可通过抑制IL-36通路发挥抗炎的生物学效应。根据研究分析结果显示，相比于安慰剂， HB0034单次静脉给药后的第1周GPP发作患者的皮肤脓疱得到明显清除，达到方案预设的主要研究终 点，安全性方面表现良好，未发现新的安全性信号。 智通财经APP讯，华海药业(600521.SH)发布公告，近日，公司下属子公司上海华奥泰生物药业股份有 限公司(简称"华奥泰")收到国家药品监督管理局签发的瑞西奇拜单抗(研发代号为：HB0034)注射液境内 生产药品注册上市许可申请的《受理通知书》。申报适应症：用于治疗成人泛发性脓疱型银屑病(GPP) 发作。 ...

Core Viewpoint - Huahai Pharmaceutical (600521.SH) announced that its subsidiary, Shanghai Huatai Biopharmaceutical Co., Ltd. (referred to as "Huatai"), has received the acceptance notice for the domestic production drug registration application of HB0034 injection from the National Medical Products Administration. This drug is aimed at treating adult generalized pustular psoriasis (GPP) [1] Group 1 - HB0034 is the first domestically developed innovative anti-IL-36R antibody in China, which can exert anti-inflammatory biological effects by inhibiting the IL-36 pathway [1] - The drug has shown significant skin pustule clearance in GPP patients one week after a single intravenous administration compared to placebo, achieving the predefined primary research endpoint [1] - Safety results for HB0034 have been favorable, with no new safety signals identified [1]

华海药业公告，公司下属子公司上海华奥泰生物药业股份有限公司收到国家药品监督管理局签发的瑞西 奇拜单抗（研发代号为：HB0034）注射液境内生产药品注册上市许可申请的《受理通知书》。该药品 用于治疗成人泛发性脓疱型银屑病（GPP）发作。目前全球范围内，尚未有国内企业自研的靶向IL-36R 抗体获批上市。HB0034作为国内首个自研创新抗IL-36R抗体，可通过抑制IL-36通路发挥抗炎的生物学 效应。根据研究分析结果显示，相比于安慰剂，HB0034单次静脉给药后的第1周GPP发作患者的皮肤脓 疱得到明显清除，达到方案预设的主要研究终点，安全性方面表现良好，未发现新的安全性信号。 ...

本公司董事会及全体董事保证本公告内容不存在虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 证券代码：600521 证券简称：华海药业 公告编号：临 2025-106 号 债券代码：110076 债券简称：华海转债 浙江华海药业股份有限公司 可转换公司债券转股结果暨股份变动公告 重要内容提示： 累计转股情况：浙江华海药业股份有限公司可转换公司债券（以下简称 "华海转债"）于2021年5月6日开始转股，截至2025年9月30日，累计共有194,000 元华海转债转为公司股份，因转股形成的股份数量为5,665股，占华海转债转股 前公司已发行股份总额的0.00039%。 未转股可转债情况：截至2025年9月30日，除已回售的可转债外（期间 公司可转债回售金额为1,000元），尚未转股的华海转债金额为1,842,405,000元， 占华海转债发行总额的99.9894%。 本季度转股情况：自2025年7月1日至2025年9月30日期间，华海转债合计 共有12,000元转为公司股份，因转股形成的股份数量为361股，占华海转债转股 前公司已发行股份总额的0.000025%。 一、可 ...

| 股票简称：华海药业 股票代码：600521 | 公告编号：临 | 号 2025-105 | | --- | --- | --- | | 债券简称：华海转债 债券代码：110076 | | | 浙江华海药业股份有限公司 关于子公司药品上市许可申请获得受理的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，浙江华海药业股份有限公司（以下简称"华海药业"或"公司"）下属子 公司上海华奥泰生物药业股份有限公司（以下简称"华奥泰"）收到国家药品监督管 理局（以下简称"国家药监局"）签发的瑞西奇拜单抗（研发代号为：HB0034）注射 液境内生产药品注册上市许可申请的《受理通知书》。现将相关情况公告如下： 一、药物基本情况 受理号：CXSS2500106 申请事项：境内生产药品注册上市许可 申请人：上海华奥泰生物药业股份有限公司 药物名称：瑞西奇拜单抗注射液 剂型：注射剂 规格：120mg（2ml）/瓶 申报适应症：用于治疗成人泛发性脓疱型银屑病（GPP）发作 注册分类：治疗用生物制品 1 类 申请人：上海华奥泰生 ...

Core Viewpoint - Huahai Pharmaceutical (600521) announced that its subsidiary, Huaotai, received the acceptance notice for the drug registration application of HB0034 injection from the National Medical Products Administration, which is intended for the treatment of adult generalized pustular psoriasis (GPP) flare-ups [1] Company Summary - Huahai Pharmaceutical's subsidiary, Huaotai, is advancing in the pharmaceutical market with the development of HB0034 injection [1] - The drug is specifically aimed at treating a significant dermatological condition, indicating potential market demand and therapeutic relevance [1] Industry Summary - The approval process for new drug applications is critical in the pharmaceutical industry, reflecting regulatory compliance and the potential for market entry [1] - The treatment of generalized pustular psoriasis represents a niche but important segment within dermatological therapies, highlighting ongoing innovation in this area [1]

Core Viewpoint - Huahai Pharmaceutical's stock has experienced fluctuations, with a year-to-date increase of 15.77% but a recent decline over various trading periods, indicating potential volatility in the market [1][2]. Financial Performance - For the first half of 2025, Huahai Pharmaceutical reported revenue of 4.516 billion yuan, a year-on-year decrease of 11.93%, and a net profit attributable to shareholders of 409 million yuan, down 45.30% year-on-year [2]. - Cumulative cash dividends since the company's A-share listing amount to 2.989 billion yuan, with 1.016 billion yuan distributed over the past three years [3]. Stock Market Activity - As of September 29, Huahai Pharmaceutical's stock price was 20.40 yuan per share, with a market capitalization of 30.544 billion yuan [1]. - The stock has seen significant trading activity, with a net inflow of 363,300 yuan from main funds and notable buying and selling volumes over recent days [1]. Shareholder Information - As of September 19, the number of shareholders increased by 28.47% to 67,300, while the average circulating shares per person decreased by 22.16% to 21,624 shares [2]. - Major shareholders include China Europe Medical Health Mixed A, which increased its holdings by 12.234 million shares, and Southern CSI 500 ETF, which also saw an increase in holdings [3].